RCT: Efficacy and safety of TRC105 plus pazopanib vs. pazopanib alone for treatment of patients with advanced angiosarcoma.

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial – JAMA Oncology

Commentaries:

Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma – The ASCO Post

Carotuximab addition to pazopanib does not improve survival in advanced angiosarcoma patients – Physician’s Weekly

Commentaries on Twitter

A phase III trial in 123 patients with advanced-stage angiosarcoma reveals no significant difference in mPFS with pazopanib plus the anti-endoglin (CD105) mAb carotuximab vs pazopanib alone: https://t.co/TPPFRNCOoC #scmsm #caxtx

— NatureRevClinOncol (@NatRevClinOncol) April 5, 2022

First randomized trial in angiosarcoma demonstrates no signif difference in progression-free survival for combo of novel angiogenesis inhibitor carotuximab + pazopanib vs. pazopanib alone in advanced angiosarcoma. https://t.co/f1Z5EjOdK2 pic.twitter.com/qf3Tez9VU2

— JAMA Oncology (@JAMAOnc) March 31, 2022